Capital is fleeing overheated memory stocks and plowing into downstream AI beneficiaries like ARKG, which already jumped 15% in just two weeks.
As tech giants sink 700 billion into AI infrastructure, investors must hide in biotech funds like ARKG that will actually harvest the real-world gains.
A newly lax FDA just triggered an 80 percent vertical spike in a gene therapy stock, so grab Cathie Wood's genomics ETF to ride the AI drug discovery wave.
AI-bio interface is the unlock for the next decade of medical fortunes, market still prices it as venture speculation.